Menu Close

Checkpoint inhibitors enhance CAR T-cell therapy in relapsed B-cell acute lymphoblastic leukemia

SAN DIEGO — Checkpoint inhibitors appeared to safely and effectively improve outcomes with CD19-directed chimeric antigen receptor T-cell therapy among children with relapsed B-cell acute lymphoblastic leukemia, according to a study presented at ASH … (본문 전체 12/1/2018 5:00 PM)